In the five-year agreement, Medtronic will be the exclusive sales agent for Kuros' product in certain U.S. spine geographies.

Kuros Biosciences USA's strategic, exclusive sales agency agreement with Medtronic could boost adoption of its MagnetOs bone ...

Kuros Biosciences AG / Key word (s): Agreement Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division 07-Jan-2025 / 07:00 CET/CEST Release of an ad ...

Medtronic and Kuros Biosciences signed a strategic agreement to support sales of the MagnetOs bone graft technology.

From new partnerships to acquisitions, here are four key developments from spine and orthopedic medtech companies since Jan. 1.

The global bone graft fixation system market is poised for substantial growth in the coming decade, with estimations ...

MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft. ‡ MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ...

underscoring a shared commitment to expanding access to Kuros' pioneering MagnetOs bone grafting technology. This agreement positions Kuros for new opportunities in the U.S. spine market and also ...

Medtronic will act as the exclusive sales agent of MagnetOsTM for Kuros Biosciences USA, Inc. in mutually agreed upon sales territories for use in spine surgeriesKuros will work collaboratively to sel ...